Deciphering Tumour Heterogeneity Of Breast Cancer Metastases Using Barcoded Patient Derived Xenografts
Funder
National Health and Medical Research Council
Funding Amount
$583,161.00
Summary
Breast cancer mortality is largely due to metastases that seed from the primary tumour. Breast tumours are known to contain a heterogeneous mix of cells, but the precise way that cells are selected for tumour growth and metastasis (as well as their response to systemic therapy) is not well understood. In this study we will use patient samples and cellular ‘barcoding’ to track the destiny of every single clone throughout disease progression and study the effect of various therapies on metastasis.
Identification Of New Therapeutic Targets In Neuroblastoma Through ABCC Transporter Associated Pathways.
Funder
National Health and Medical Research Council
Funding Amount
$591,436.00
Summary
Neuroblastoma accounts for 15% of childhood cancer deaths. Children diagnosed over 1 year have survival rates below 40%. New research shows that certain genes previously implicated in drug resistance contribute to neuroblastoma development. We will investigate their role using a new neuroblastoma model and a range of biochemical and cell biology techniques. This research will improve our understanding of neuroblastoma biology and identify new therapeutic targets in this and other cancers.
Improving Outcomes For Women Diagnosed With Mucinous Ovarian Cancer
Funder
National Health and Medical Research Council
Funding Amount
$598,238.00
Summary
Mucinous ovarian cancer (MOC) is different from other ovarian cancers but few studies have characterized the genetic changes specific to this subtype. It is often confused with metastases from other organs and does not respond well to standard ovarian cancer therapies. If MOC is more similar to mucinous cancers from other organs than other ovarian cancers, it may be better treated with chemotherapeutics that show success with other mucinous tumours.
Sympathetic Nervous System Regulation Of The Tumour Microenvironment
Funder
National Health and Medical Research Council
Funding Amount
$396,212.00
Summary
Metastasis is the major cause of morbidity and mortality in breast cancer. These studies will evaluate the translational opportunity of targeting the sympathetic nervous system as a common regulator of cancer progression pathways. By exploiting sensitive imaging technology for non-invasive, real-time assessment of stress biology, these studies will define the neuroendocrine mechanisms that operate in the tumour microenvironment to support dissemination and arrest of cancer cells in target organs ....Metastasis is the major cause of morbidity and mortality in breast cancer. These studies will evaluate the translational opportunity of targeting the sympathetic nervous system as a common regulator of cancer progression pathways. By exploiting sensitive imaging technology for non-invasive, real-time assessment of stress biology, these studies will define the neuroendocrine mechanisms that operate in the tumour microenvironment to support dissemination and arrest of cancer cells in target organs.Read moreRead less
Improving Anti-cancer Therapy By Stromal Targeting And Remodelling
Funder
National Health and Medical Research Council
Funding Amount
$673,742.00
Summary
We have developed a new drug which binds to abnormal cancer blood vessels. Upon binding, shape and tone of cancer vessels are restored and they become tighter. Our research will now test whether combining this new drug with current standard-of-care therapies such as chemo- and immunotherapy, will improve cytotoxic drugs and also make the immune system work better to fight the cancer. We also expect that tightening of blood vessels will stop cancer cells from spreading throughout the body.
Elucidating The Function Of Rho-ROCK Signalling In The Regulation Of Cancer Progression
Funder
National Health and Medical Research Council
Funding Amount
$636,568.00
Summary
As cancers progress from benign to more malignant forms, the way in which cancer cells respond to external influences changes dramatically. These cells subvert the normal interactions between proteins which pass signals from outside the cell to the inside, to control cell behaviour and assume a survival advantage. We plan to study a form of cell signalling that is often abnormal in cancer in order to identify technologies for limiting cancer growth and spread by interfering with these signals.
Overweight individuals have an increased risk for developing liver cancer. This may be due to the reduced production of the fat-derived hormone adiponectin. Reduced levels of adiponectin are associated with increased inflammation and liver disease. Using mice not expressing adiponectin we will test its importance in liver cancer growth. The proposed research will provide a better understanding of the factors that promote liver cancer formation.
Small Molecule Inhibitors To Reprogram The Tumour Environment And Improve Immunotherapy
Funder
National Health and Medical Research Council
Funding Amount
$784,520.00
Summary
Cancer blood vessels are different to normal blood vessels; they help cancer cells to spread and stop immune cells in their tracks. We have identified drugs which help to make cancer blood vessels more normal and also bring immune cells into the cancer core. We will test these drugs in combination with immunotherapies, a new treatment option which has not reached its full potential in the clinic. Since our drug candidates are already in clinical use, we expect to fast track clinical development.
Regulation Of Breast Cancer Metastasis By MiR-193b And MiR-342-3p
Funder
National Health and Medical Research Council
Funding Amount
$581,537.00
Summary
When breast cancer spreads to other organs, it results in high morbidity and mortality. MicroRNAs are a class of genes that control the expression of other genes, some of which are involved in the spread of cancer. In this project we will examine the function of two microRNA species that we have found to be associated with breast cancer spread. The anticipated outcome is a better knowledge of the genes that control cancer spread and the identification of new molecular targets for therapy.
Circulating Tumour DNA As A Marker Of Complete Pathological Response And Long Term Outcome For Locally Advanced Rectal Cancer Treated With Pre-operative Chemoradiotherapy
Funder
National Health and Medical Research Council
Funding Amount
$613,183.00
Summary
Rectal cancers are often treated by chemoradiotherapy (CRT) followed by surgery which may result in long-term stoma. A significant proportion of these patients can achieve complete remission to CRT alone. This project will assess the accuracy of a promising blood marker (circulating tumour DNA) for predicting response to treatment in patients with rectal cancer undergoing CRT. If confirmed to be a reliable marker, this test could be used to select patients who may be able to avoid or delay surge ....Rectal cancers are often treated by chemoradiotherapy (CRT) followed by surgery which may result in long-term stoma. A significant proportion of these patients can achieve complete remission to CRT alone. This project will assess the accuracy of a promising blood marker (circulating tumour DNA) for predicting response to treatment in patients with rectal cancer undergoing CRT. If confirmed to be a reliable marker, this test could be used to select patients who may be able to avoid or delay surgery.Read moreRead less